spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

BioIVT Launches Dissociated Tumor Cell DTC Product Line to Advance Oncology Research

DTCs are primary cancer cells that are prepared with minimal manipulation and closely mimic tumor behavior.

Westbury, NY – Sept. 6, 2018 – BioIVT, a leading provider of research models and services for drug development, today announced the addition of a dissociated tumor cell (DTC) product line to its immunology portfolio.

“DTCs are patient-derived primary tumor cells isolated from fresh tumor tissue using only mechanical and enzymatic dissociation. As a result of this minimal manipulation, DTCs most closely resemble the tumor and are extremely valuable tools for oncology research,” said BioIVT Sr. Director, Biological Operations Wini Luty, MS. “Since BioIVT acquired Asterand Bioscience™ in August 2017, we have gained greater access to disease-state tissue. As a result, we are now able to provide more tissue product derivatives, such as DTCs, to meet our clients’ specific research needs.”

Researchers can use patient-derived DTCs to determine how specific cohorts of cancer cells will react to different drug therapies. DTCs provide the closest representation of the clinical scenario. While no two patients’ tumors are identical, there is a greater likelihood of a therapy being effective if it has been previously tested on DTCs from patients with similar donor demographics and health issues. In this way, DTCs can help to advance personalized medicine.

DTCs can also be incorporated into 3D micro-tumor arrays to provide highly efficient, high-throughput drug screening and chemosensitivity testing.

BioIVT is initially providing DTC lots from kidney, ovarian, liver, breast, colon, and lung tumors. Clients can also request matched sets of DTCs with peripheral blood mononuclear cells, normal tumor-adjacent tissue or tumor tissue.

As offering high-quality products is a BioIVT top priority, a pathologist reviews each tumor sample at collection to confirm that it is the correct tissue and organ site and that the diagnosis matches the clinical data.

BioIVT quality control processes also ensure that all the cell lots are sterile and pathogen-free. In addition, a small portion of cells from each lot are thawed and grown to confluency in cell culture to ensure that they are viable and will grow as expected by the client. All such information is detailed on the Certificate of Analysis accompanying the cell lot.

About BioIVT

BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

PCI Announces Expansion of High Potent Tableting and Powder Modification Capacity

Philadelphia, USA – March 25, 2019 PCI Pharma Services (PCI), full-service provider of specialist outsourced drug manufacturing, clinical trial services, and commercial packaging to the global biopharmaceutical industry, has announced further investment to expand its flagship manufacturing center in Tredegar, Wales.
More info >>


White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

Industry Events

ChinaBio® Partnering Forum 2019

8-9 May 2019, Shanghai, China

Access a world of opportunities through life science partnering in China. ChinaBio® Partnering Forum is the premier life science partnering event in China. The conference will be held May 8–9 in Shanghai, attracting biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement